Application of micropatterned cocultured hepatocytes to evaluate the inductive potential and degradation rate of major xenobiotic metabolizing enzymes

Drug Metabolism and Disposition

Volumn 44, Issue 2, 2016, Pages 250-261

  Dixit, Vaishali ^a   Moore, Amanda ^a   Tsao, Hong ^a   Hariparsad, Niresh ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MESSENGER RNA; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; CYTOCHROME P450; XENOBIOTIC AGENT;

ARTICLE; COCULTURE; CONTROLLED STUDY; CYP2B6 GENE; CYP3A4 GENE; DRUG BINDING; DRUG METABOLISM; EC50; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INDUCTION; GENE EXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; LIVER CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CULTURE; LIVER CELL; METABOLISM; PHYSIOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; HALF-LIFE; HEPATOCYTES; HUMANS; PHENOBARBITAL; PHENYTOIN; RIFAMPIN; RNA, MESSENGER; XENOBIOTICS;

EID: 84958169917     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067173     Document Type: Article

References (37)

1. Bachmann A, Moll M, Gottwald E., Nies C, Zantl R, Wagner H., Burkhardt B, Sánchez JM, Ladurner R., Thasler W, Damm G and Nussler A (2015) 3D Cultivation Techniques for Primary Human Hepatocytes. Microarrays 4:64-83.
2. Berthiaume F, Moghe PV, Toner M, and Yarmush ML (1996) Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration. FASEB J 10:1471-1484.
3. Buxboim A, Ivanovska IL, and Discher DE (2010) Matrix elasticity, cytoskeletal forces and physics of the nucleus: how deeply do cells 'feel' outside and in? J Cell Sci 123:297-308.
4. Chan TS, Yu H, Moore A., Khetani SR, Tweedie D, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024-2032.
5. Chen Y and Goldstein JA (2009) The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 10:567-578.
6. Dixit V, Hariparsad N, Li F., Desai P, Thummel KE, and Unadkat JD (2007) Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853-1859.
7. Einolf HJ, Chen L, Fahmi O.A., Gibson CR, Obach RS, Shebley M, Silva J., Sinz MW, Unadkat JD, and Zhang L, et al. (2014) Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther 95:179-188.
8. Fahmi OA, Kish M, Boldt S., and Obach RS (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605-1611.
9. Faucette SR, Sueyoshi T, Smith C.M., Negishi M., Lecluyse EL, and Wang H (2006) Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 317:1200-1209.
10. Faucette SR, Zhang TC, Moore R, Sueyoshi T., Omiecinski CJ, LeCluyse EL, Negishi M, and Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72-80.
11. Garg V, Chandorkar G, Yang Y., Adda N, McNair L, Alves K., Smith F, and van Heeswijk RP (2013) The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 75:431-439.
12. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
13. Gómez-Lechón MJ, Jover R, Donato T, Ponsoda X, Rodriguez C, Stenzel KG, Klocke R, Paul D, Guillén I, and Bort R, et al. (1998) Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J Cell Physiol 177:553-562.
14. Hirano M, Maeda K, Shitara Y., and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
15. Imai H, Kotegawa T, Tsutsumi K., Morimoto T, Eshima N, Nakano S., and Ohashi K (2008) The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol 65:701-707.
16. Inoue K, Inazawa J, Suzuki Y., Shimada T, Yamazaki H, Guengerich F.P., and Abe T (1994) Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1. Jpn J Hum Genet 39: 337-343.
17. Kharasch ED, Francis A, London A., Frey K, Kim T, and Blood J (2011) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther 90:100-108.
18. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
19. Knoell KR, Young TM, and Cousins ES (1998) Potential interaction involving warfarin and ritonavir. Ann Pharmacother 32:1299-1302.
20. Küblbeck J., Jyrkkärinne J, Molnár F, Kuningas T., Patel J, Windshügel B, Nevalainen T., Laitinen T, Sippl W, and Poso A, et al. (2011) New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol Pharm 8:2424-2433.
21. Magnusson MO, Dahl ML, Cederberg J, Karlsson M.O., and Sandström R (2008) Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther 84:52-62.
22. Nakajima A, Fukami T, Kobayashi Y., Watanabe A, Nakajima M, and Yokoi T (2011) Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 82:1747-1756.
23. Niemi M, Kivistö KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, and Eichelbaum M (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 16:565-568.
24. Ramsden D, Tweedie DJ, St George R, Chen LZ, and Li Y (2014) Generating an in vitro-in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a rat hepatocyte model (HepatoPac). Drug Metab Dispos 42:407-414.
25. Ramsden D, Zhou J, and Tweedie DJ (2015) Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac. Drug Metab Dispos 43:1307-1315.
26. Reitman ML, Chu X, Cai X., Yabut J, Venkatasubramanian R, Zajic S., Stone JA, Ding Y, Witter R, and Gibson C, et al. (2011) Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234-242.
27. Renwick AB, Watts PS, Edwards R.J., Barton PT, Guyonnet I, Price RJ, Tredger J.M., Pelkonen O., Boobis AR, and Lake BG (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 28:1202-1209.
28. Sahi J, Shord SS, Lindley C, Ferguson S., and LeCluyse EL (2009) Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 23: 43-58.
29. Tirona RG, Leake BF, Wolkoff A.W., and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
30. Trask OJ, Jr, Moore A, and LeCluyse EL (2014) A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. Assay Drug Dev Technol 12: 16-27.
31. Wang WW, Khetani SR, Krzyzewski S, Duignan D.B., and Obach RS (2010) Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 38:1900-1905.
32. Yajima K, Uno Y, Murayama N., Uehara S, Shimizu M, Nakamura C., Iwasaki K, Utoh M, and Yamazaki H (2014) Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. Drug Metab Dispos 42:867-871.
33. Yamaguchi H, Takeuchi T, Okada M., Kobayashi M, Unno M, Abe T., Goto J, Hishinuma T, Shimada M., and Mano N (2011) Screening of antibiotics that interact with organic aniontransporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull 34: 389-395.
34. Yang J, Liao M, Shou M., Jamei M, Yeo KR, Tucker G.T., and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
35. Zamek-Gliszczynski M.J., Mohutsky MA, Rehmel J.L., and Ke AB (2014) Investigational smallmolecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk. Drug Metab Dispos 42:1008-1015.
36. Zhang JG, Ho T, Callendrello A.L., Clark RJ, Santone EA, Kinsman S, Xiao D., Fox LG, Einolf HJ, and Stresser DM (2014) Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytes. Drug Metab Dispos 42:1379-1391.
37. Zhu Q, Xia H, Xia C.Q., Yang Q., Doshi U, Li AP, and Liao M (2014) Culture duration-, donor-, and medium-dependent changes in OATP1B3-mediated telmisartan uptake in human hepatocytes. Drug Metab Lett 7:117-125.